Related Experiment Video
Updated: Jun 23, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice
1Queen of the Valley Medical Center, 1000 Trancas St, Napa, CA 94558, USA. stacyhealy@sbcglobal.net
Alterations in hemostasis and coagulation are common problems during critical illness. For that reason, it is essential that advanced practice and critical care nurses have an understanding of the medications used to treat these potentially deadly disorders. The antithrombotic drugs, including anticoagulants, antiplatelet agents, and fibrinolytics, are among the most frequently used drug therapies in the United States. These agents prevent and treat the thrombotic diseases, a leading cause of morbidity and mortality. Anticoagulants, the indirect and direct thrombin inhibitors as well as the vitamin K antagonists, are critical in treating venous thrombosis and preventing serious thrombotic complications with atrial fibrillation. The antiplatelet drugs work to decrease platelet aggregation and are especially effective in preventing and managing arterial thrombus. On the other end of the spectrum, the procoagulants are used to help prevent and control blood loss. These agents include human blood stimulators, human factor concentrates, including recombinant activated factor VIIa, and desmopressin.
Alterations in hemostasis and coagulation are common problems during critical illness. For that reason, it is essential that advanced practice and critical care nurses have an understanding of the medications used to treat these potentially deadly disorders. The antithrombotic drugs, including anticoagulants, antiplatelet agents, and fibrinolytics, are among the most frequently used drug therapies in the United States. These agents prevent and treat the thrombotic diseases, a leading cause of morbidity and mortality. Anticoagulants, the indirect and direct thrombin inhibitors as well as the vitamin K antagonists, are critical in treating venous thrombosis and preventing serious thrombotic complications with atrial fibrillation. The antiplatelet drugs work to decrease platelet aggregation and are especially effective in preventing and managing arterial thrombus. On the other end of the spectrum, the procoagulants are used to help prevent and control blood loss. These agents include human blood stimulators, human factor concentrates, including recombinant activated factor VIIa, and desmopressin.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management

